--- title: "JPMorgan Chase & Co. Increases Aktis Oncology (NASDAQ:AKTS) Price Target to $33.00" type: "News" locale: "en" url: "https://longbridge.com/en/news/292641557.md" description: "JPMorgan Chase raised its price target for Aktis Oncology (NASDAQ:AKTS) from $30.00 to $33.00, maintaining an 'overweight' rating. This follows similar upgrades by other analysts, including HC Wainwright and Raymond James, contributing to a consensus 'Moderate Buy' rating with an average target of $34.60. The stock rose 2.4% during trading." datetime: "2026-07-14T14:18:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292641557.md) - [en](https://longbridge.com/en/news/292641557.md) - [zh-HK](https://longbridge.com/zh-HK/news/292641557.md) generator: "portal-rs" --- # JPMorgan Chase & Co. Increases Aktis Oncology (NASDAQ:AKTS) Price Target to $33.00 Aktis Oncology (NASDAQ:AKTS - Get Free Report) had its price target upped by JPMorgan Chase & Co. from $30.00 to $33.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an "overweight" rating on the technology company's stock. JPMorgan Chase & Co.'s price objective indicates a potential upside of 25.93% from the company's previous close. Get **Aktis Oncology** alerts: - A Fresh IPO That Long-Term Investors Shouldn’t Ignore A number of other analysts have also recently weighed in on AKTS. HC Wainwright upped their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a "buy" rating in a research report on Tuesday, June 2nd. Raymond James Financial started coverage on Aktis Oncology in a research report on Monday, June 15th. They issued a "strong-buy" rating and a $40.00 price objective on the stock. Weiss Ratings upgraded Aktis Oncology from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, June 23rd. Finally, William Blair began coverage on Aktis Oncology in a research report on Wednesday, April 29th. They issued an "outperform" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $34.60. **Check Out Our Latest Stock Report on Aktis Oncology** ## Aktis Oncology Stock Up 2.4% NASDAQ AKTS traded up $0.62 during mid-day trading on Tuesday, hitting $26.20. The company's stock had a trading volume of 62,544 shares, compared to its average volume of 347,510. The stock has a market cap of $1.40 billion and a price-to-earnings ratio of -69.58. Aktis Oncology has a 52-week low of $14.72 and a 52-week high of $34.19. The company has a fifty day moving average price of $22.89. Aktis Oncology (NASDAQ:AKTS - Get Free Report) last released its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The business had revenue of $1.87 million for the quarter. As a group, research analysts anticipate that Aktis Oncology will post -1.62 earnings per share for the current year. ## Aktis Oncology Company Profile (Get Free Report) Aktis Oncology NASDAQ: AKTS is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments. The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones. ## Featured Articles - Five stocks we like better than Aktis Oncology - The Bond Market Just Sent Amazon a Message Investors Shouldn’t Ignore - Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings - Insiders Sell 2 AI Enablers: Investors Can Buy Into Their Futures - Beyond the Foundry: 5 Infrastructure Stocks Tackling the AI Bottlenecks *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Aktis Oncology Right Now? Before you consider Aktis Oncology, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aktis Oncology wasn't on the list. While Aktis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [AKTS.US](https://longbridge.com/en/quote/AKTS.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [RJF.US](https://longbridge.com/en/quote/RJF.US.md) - [AMZN.US](https://longbridge.com/en/quote/AMZN.US.md) - [SNDK.US](https://longbridge.com/en/quote/SNDK.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) - [RJF-B.US](https://longbridge.com/en/quote/RJF-B.US.md) ## Related News & Research - [Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations](https://longbridge.com/en/news/295844401.md) - [Aktis Oncology (NASDAQ:AKTS) Given Average Recommendation of "Buy" by Analysts](https://longbridge.com/en/news/278388718.md) - [Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.](https://longbridge.com/en/news/296643850.md) - [iSpecimen ships hundreds of cancer blood specimens for international research order within three weeks](https://longbridge.com/en/news/296531044.md) - [WellSpan and Johns Hopkins renew partnership for advanced cancer care access](https://longbridge.com/en/news/296596329.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**